Weaponizing truly individualized therapies

The 4th Annual European NeoAg Summit is the leading industry-dedicated meeting focused on advancing personalised cancer immunotherapy through neoantigen targeting. Over the last year, there has been a record number of neoantigen-based therapies heading into and through the clinic. In addition, exciting collaborations that bring significant investment into the space means that tumour-specific antigen targeting is set to explode. At the European NeoAg Summit, we bring together the leading pharma and biotech companies to discuss:

• Reducing the discordance between various neoantigen prediction methods
• Maximising the immune response to neoantigens
• Shortening the needle-to-needle time of personalised cancer immunotherapy
• Navigating the evolving regulatory landscape to faster approval

Join the leaders from BioNTech, Genentech, Genocea, Gritstone Oncology, Agenus, Ziopharm, Vaccibody and many more to spur on more efficacious personalised cancer vaccines and cell therapies.